Skip to main content
. Author manuscript; available in PMC: 2013 May 1.
Published in final edited form as: Circulation. 2007 Jul 23;116(6):654–663. doi: 10.1161/CIRCULATIONAHA.106.672451

Figure 6.

Figure 6

SDF-1α protects myocytes from hypoxia/reoxygenation-induced cell death. Cultured myocytes were treated with 25 nmol/L SDF-1α or vehicle before exposure to 1 hour of hypoxia followed by 18 hours of reoxygenation. Myocytes also were treated with 40 μmol/L AMD3100 for 4 hours before the addition of SDF-1α. Cell death was assessed by trypan blue exclusion and LDH release. A, Trypan blue exclusion assay demonstrated increased cell death in hypoxia, which was prevented by SDF-1α (25 nmol/L); AMD3100 blocked the effects of SDF-1α. B, ERK and AKT inhibition by 20 μmol/L PD98059 and 20 μmol/L LY294002 blocks SDF-1α protection from hypoxia/reoxygenation, decreasing trypan blue cell exclusion. C, LDH release was highest in the hypoxia group; this was prevented by SDF-1α, and the effect was reversed by AMD3100. D, ERK and AKT inhibition by 20 μmol/L PD98059 and 20 μmol/L LY294002 blocks SDF-1α protection from hypoxia/reoxygenation, increasing LDH release. Values are mean±SEM. *P<0.05 vs normoxia (Nx), **P<0.01 vs Nx, †P<0.05 vs hypoxia (Hx). n = 3.